FTM
First Turn Management Portfolio holdings
AUM
$536M
This Quarter Return
+20%
1 Year Return
+36.36%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$632M
AUM Growth
+$632M
(+2.7%)
Cap. Flow
-$29.6M
Cap. Flow
% of AUM
-4.68%
Top 10 Holdings %
Top 10 Hldgs %
39.33%
Holding
49
New
13
Increased
6
Reduced
19
Closed
11
Top Buys
| 1 |
Natera
NTRA
|
$19.8M |
| 2 |
Arcellx
ACLX
|
$17.9M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$16.5M |
| 4 |
Harrow
HROW
|
$14.7M |
| 5 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$14.3M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$28.7M |
| 2 |
Immunovant
IMVT
|
$18.4M |
| 3 |
DexCom
DXCM
|
$18.2M |
| 4 |
Alphatec Holdings
ATEC
|
$14.2M |
| 5 |
IDEAYA Biosciences
IDYA
|
$14M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Enliven Therapeutics
ELVN
$1.24B
| $13.7M | 2.16% |
535,092
+121,849
| +29% | +$3.11M |
|
27
ADMA Biologics
ADMA
$4.03B
| $13.3M | 2.1% |
+664,985
| New | +$13.3M |
|
28
Day One Biopharmaceuticals
DAWN
$766M
| $13.2M | 2.09% |
+947,878
| New | +$13.2M |
|
29
Repligen
RGEN
$6.54B
| $13.2M | 2.09% |
+88,714
| New | +$13.2M |
|
30
Xenon Pharmaceuticals
XENE
$2.99B
| $12.8M | 2.03% |
325,218
-14,658
| -4% | -$577K |
|
31
Glaukos
GKOS
$5.42B
| $12.5M | 1.98% |
+96,097
| New | +$12.5M |
|
32
Krystal Biotech
KRYS
$4.35B
| $12.4M | 1.96% |
67,942
-41,280
| -38% | -$7.51M |
|
33
Cytokinetics
CYTK
$5.98B
| $11.8M | 1.87% |
223,147
-70,171
| -24% | -$3.71M |
|
34
Rocket Pharmaceuticals
RCKT
$358M
| $11.5M | 1.82% |
621,306
+60,317
| +11% | +$1.11M |
|
35
BridgeBio Pharma
BBIO
$9.91B
| $10.2M | 1.61% |
+399,781
| New | +$10.2M |
|
36
Relay Therapeutics
RLAY
$709M
| $8.68M | 1.37% |
+1,226,354
| New | +$8.68M |
|
37
ARS Pharmaceuticals
SPRY
$1.08B
| $8.6M | 1.36% |
+593,291
| New | +$8.6M |
|
38
KalVista Pharmaceuticals
KALV
$713M
| $4.11M | 0.65% |
355,000
-704,540
| -66% | -$8.16M |
|
39
Immunocore
IMCR
$1.78B
| – | – |
-291,086
| Closed | -$9.86M |
|
|
40
Immunovant
IMVT
$2.91B
| – | – |
-695,428
| Closed | -$18.4M |
|
41
Disc Medicine
IRON
$2.14B
| – | – |
-138,907
| Closed | -$6.26M |
|
42
Apogee Therapeutics
APGE
$2.27B
| – | – |
-318,327
| Closed | -$12.5M |
|
|
43
Alphatec Holdings
ATEC
$2.32B
| – | – |
-1,360,410
| Closed | -$14.2M |
|
|
44
DexCom
DXCM
$30.9B
| – | – |
-160,096
| Closed | -$18.2M |
|
|
45
IDEAYA Biosciences
IDYA
$2.26B
| – | – |
-397,782
| Closed | -$14M |
|
46
Revolution Medicines
RVMD
$7.43B
| – | – |
-329,519
| Closed | -$12.8M |
|
|
SLN
47
Silence Therapeutics
SLN
$237M
| – | – |
-537,338
| Closed | -$10.2M |
|
|
48
Sarepta Therapeutics
SRPT
$1.98B
| – | – |
-181,669
| Closed | -$28.7M |
|
49
Spyre Therapeutics
SYRE
$1.02B
| – | – |
-464,435
| Closed | -$10.9M |
|